Pituitary beta-endorphin, naloxone, and feeding in several experimental obesities.
The role of beta-endorphin in the development of several obesity syndromes was examined. Adult female hooded rats received ventromedial hypothalamic lesions, dorsolateral tegmental lesions, parasagittal hypothalamic knife cuts, intraventricular 5,7-dihydroxytryptamine, ovariectomy, control surgery, or were deprived to 75% of normal body weight. Dose-dependent suppression of food intake by the opiate antagonist naloxone (0.5, 1.8, 6.8, or 25.0 mg/kg, ip) was measured during once-daily 4-h food access periods. No difference was found among the groups at any dose. Pituitary beta-endorphinlike immunoreactivity (BELI) was substantially decreased in knife-cut rats, but was unaltered by other treatments. Obesity had no effect on BELI. In another experiment, rats made obese by prolonged maintenance on palatable foods had elevated pituitary BELI levels. Feeding mechanisms involving opioid peptides do not appear to be of etiological significance in the syndromes examined.
D015116:5,7-Dihydroxytryptamine / Q000494:pharmacology; D000818:Animals; D002369:Castration; D004723:Endorphins / Q000032:analysis*; D005247:Feeding Behavior / Q000187:drug effects; D005260:Female; D007031:Hypothalamus / Q000503:physiopathology*; D009270:Naloxone / Q000494:pharmacology*; D009765:Obesity / Q000503:physiopathology*; D010902:Pituitary Gland / Q000187:drug effects / Q000503:physiopathology*; D051381:Rats; D001615:beta-Endorphin
D004723:Endorphins; D015116:5,7-Dihydroxytryptamine; D009270:Naloxone; D001615:beta-Endorphin